Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial

A Carpio,^{1,2} E A Kelvin,^{2,3} E Bagiella,⁴ D Leslie,^{5,6} P Leon,⁷ H Andrews,^{3,4} W A Hauser,^{2,8} the Ecuadorian Neurocysticercosis Group

See Editorial Commentary, p 978

¹ School of Medicine, University of Cuenca, Cuenca, Ecuador; ² GH Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, USA; ³ Data Coordinating Center at the New York State Psychiatric Institute and Columbia University, New York, USA; ⁴ Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, USA; ⁵ MRI Diagnostics of Westchester, New York, USA; ⁶ Good Samaritan Hospital, Suffern, New York, USA; ⁷ Instituto de Diagnóstico por Imágenes, Cuenca, Ecuador; ⁸ Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, USA

Correspondence to: W A Hauser, Gertrude H Sergievsky Center, Columbia University, 622 West 168th Street, New York, NY 10032, USA; wahausera@optonline.net

Received 18 January 2008
Revised 27 March 2008
Accepted 1 April 2008
Published Online First
21 May 2008

ABSTRACT

Aim: The aim of this trial was to evaluate the effects of albendazole (ALB) on cyst disappearance, reduction of the number of cysts and seizure recurrence.

Methods: 178 patients with new onset symptoms due to active or transitional neurocysticercosis were randomly assigned to receive either 800 mg of ALB daily or placebo for 8 days. All patients also received prednisone. Imaging studies were done at baseline and at months 1, 6 and 12 of follow-up.

Results: Active cysts were identified in 59 of 88 people randomised to ALB and 57 of the 90 in the placebo arm. By 1 month, 31% were free of active cysts in the treatment group compared with 7% in the placebo group ($p = 0.001$). In addition, the ALB group had a greater reduction in the number of active cysts compared with the placebo group ($p = 0.001$). After 1 month following treatment there was no additional gain by treatment group in the disappearance or reduction in the number of active cysts. ALB treatment had little effect on cysts in the transitional or calcification stage. We found no difference between the ALB and placebo groups in symptoms during treatment or in seizure recurrence during the 12 months after treatment.

Conclusion: Albendazole plus symptomatic treatment leads to the disappearance of active cysts in 31% of patients compared with 7% of those with symptomatic treatment alone. This treatment effect occurs within the first 30 days after treatment.

Trial registration number: NCT00283699.

Neurocysticercosis (NC), the infection caused by the larval stage of the tapeworm *Taenia solium*, is the most frequently occurring parasitic disease affecting the human CNS.¹ The disease is associated with clinical manifestations such as seizures, headache and focal neurological deficits.^{1,2} NC is a serious public health problem for most of the developing world as well as for developed countries with high immigration rates from endemic countries in Latin America, Asia and Africa.² NC has been designated as an emerging infection by the US Centers for Disease Control.^{3,4}

A number of studies have been published related to treatment for NC with antihelminthic drugs (AHD), such as praziquantel and albendazole (ALB).^{5–10} Although treatment should cause earlier degeneration of cysticerci and could therefore decrease the risk of persistent neurological symptoms,⁷ there are concerns that seizures and other neurological events can be triggered by the inflammatory reaction to treatment induced cysticercal degeneration.⁶ Frequently, spontaneous resolution of parenchymal cysticerci is observed on

serial imaging studies.⁹ A systematic review of the literature stated that there is insufficient evidence to conclude that AHD treatment is associated with therapeutic benefit in NC⁹ and a recent meta-analysis of NC treatment concluded that there was evidence of only a modest effect of drug treatment in patients with NC.¹¹ To date, there remains a debate over the value and safety of AHD therapy.^{9,12}

This paper reports the results of a double blind, randomised, placebo controlled trial to evaluate the effects of ALB treatment on cyst disappearance, reduction in the number of cysts and seizure recurrence in patients with NC.

METHODS

Participants

Patients were recruited from six hospitals in Ecuador: three in Quito, two in Cuenca and one in Guayaquil. Approval for the study was granted by the Institutional Review Board of Columbia University, the Office for Human Research Protection (OHRP) of the National Institutes of Health in the USA, as well as the ethics committees at each of the participating hospitals.

Patients of any age or gender were eligible to participate if they had experienced new onset of symptoms associated with NC within 2 months prior to recruitment and had active and/or transitional NC cysts identified on axial CT or MRI of the brain. Non-inclusion criteria included having only calcifications, pregnancy, papilloedema, active tuberculosis, syphilis, ocular cysticercosis, active gastric ulcers or any progressive or life-threatening disorder. Patients who had received AHD during the year preceding presentation or who had received steroids within 30 days of presentation were also ineligible. Midway through the study, patients with ventricular shunt were excluded for safety concerns.

Diagnostic criteria for neurocysticercosis

A diagnosis of NC was made if a patient met any of the following criteria:¹³

1. *One or more active parenchymal cysts:* the CT scan shows circumscribed, rounded, hypodense areas without contrast enhancement. The MRI shows a CSF-like intensity signal on all sequences with no surrounding high signal. Both MRI and CT may show a high intensity or hyperdense 2–4 mm mural nodule depicting the scolex in the interior of the cyst.
2. *One or more transition or degenerative parenchymal cysts:* the CT scan shows annular contrast enhancement, surrounded by irregular

perilesional oedema; there is a diffuse hypodense area with irregular borders on non-contrast CT, or a small, hyperdense, nodule surrounded by oedema. On MRI, the fluid content is of higher signal than CSF on T1 and T2 weighted images. The cyst capsule exhibits of low signal on the T2 images, is surrounded by oedema and enhances on gadolinium enhanced T1 weighted images.

3. Any of the above descriptions associated with an extra-parenchymal location.

Interventions

For participants weighing more than 50 kg, active treatment consisted of 400 mg of ALB given orally every 12 h for 8 days. This dose has been used in other trials^{5 14} and longer duration of treatment does not seem to have any advantage.¹⁴ For participants weighing less than 50 kg (including children), a dose of 15 mg/kg/day for 8 days was prescribed, as suggested by the drug manufacturers.¹⁵ The study pharmacist prepackaged bottles of 32 active drug (200 mg ALB tablets) or 32 identical looking placebo tablets identified only by an assigned letter to maintain the blinding of study staff. The study nurse dispensed the drug in hospital and directly observed the patient taking the medication.

All patients received prednisone. Participants weighing 50 kg or more received 75 mg of prednisone daily for 8 days, then 50 mg/day for 1 week and finally 25 mg/day for 1 week. Participants weighing less than 50 kg were prescribed 1.5 mg/kg/day for 8 days, then 1 mg/kg/day for 1 week and finally

0.5 mg/kg/day for 1 week. Patients with newly occurring seizures were prescribed phenytoin at standard doses. Carbamazepine was substituted if phenytoin was contra-indicated or if seizure control was not achieved with phenytoin.

At enrolment, patients were interviewed to collect information on demographics and symptoms. In addition, a study related brain CT or MRI with and without contrast was taken within 2 weeks of enrolment.

During treatment, the study nurse monitored patients daily for adverse events, using a precoded symptom checklist. Information on symptoms was also collected at each follow-up visit in a similar manner. An independent safety monitoring committee was established to review the safety of all enrolled patients on an ongoing basis.

The research staff in Ecuador entered all data into a web based database using Scientific Web based Information Management Software (SBS Inc.), located on a server at Columbia University. The rate of data entry error was consistently found to be less than 2%.

CT and MRI images were posted to a secure website from which they were accessible for reading by two neuroradiologists, one in Ecuador and one in the USA. Follow-up images were of the same type (CT or MRI) as the baseline image in order to make comparisons. Each scan was read independently, without knowledge of treatment arm or results of prior scans. Information collected from each scan included number of cysts of each phase (active, transitional and inactive calcification) by brain location. The inter-rater reliability of the readings was fair

Figure 1 Flow diagram of a multicentre trial comparing albendazole with placebo in patients with neurocysticercosis.

Table 1 Characteristics of the patients at baseline

Characteristic	Albendazole (n = 88)	Placebo (n = 90)
Demographic information		
Age (y) (mean (SE))	39.39 (17.79)	41.55 (16.80)
Children (<18 y) (No (valid %))	8 (9.2)	7 (8.0)
Males (No (valid %))	51 (58.6)	46 (52.9)
Females (No (valid %))	36 (41.4)	41 (47.1)
Missing age and gender information (n)	1	3
Cyst phase and location		
Active cysts (No (valid %))	59 (68.6)	57 (66.3)
Transitional (No (valid %))	49 (57.0)	54 (66.8)
Calcifications (No (valid %))	38 (44.2)	32 (37.2)
Parenchymal cysts (No (valid %))	74 (86.0)	74 (82.2)
Active parenchymal cysts	45 (52.3)	39 (45.3)
Transitional parenchymal cysts	40 (46.5)	52 (60.5)
Calcified parenchymal cysts	35 (40.7)	31 (36.0)
Extraparenchymal cysts (No (valid %))	35 (40.7)	42 (48.8)
Active extraparenchymal cysts	28 (32.6)	30 (34.9)
Transitional extraparenchymal cysts	11 (12.8)	13 (15.1)
Calcified parenchymal cysts	7 (8.1)	7 (8.1)
Missing baseline scan (n)	2	4
Most common symptoms		
Headache (No (valid %))	60 (68.2)	64 (71.1)
Seizures (No (valid %))	51 (59.3)	56 (64.4)
Dizziness (No (valid %))	16 (18.6)	28 (32.2)
Gait problems (No (valid %))	13 (15.1)	17 (19.5)
Limb weakness (No (valid %))	13 (15.1)	9 (10.3)
Depression and/or anxiety (No (valid %))	15 (15.1)	17 (19.5)

*Categories are not mutually exclusive; patients may have had cysts of more than one type and in more than one location and may have experienced multiple symptoms.

to good,¹⁶ with kappa values ranging from 0.4 to 0.7 for identifying that a patient had cysts in a specific location or phase.

Sample size and randomisation

Sample size was determined for the primary outcome (the proportion of patients free of active cysts at 6 months). A sample size of 270 patients was estimated to be necessary to have 90% power to detect a response rate difference of 18% or more between the two groups.

Patients were allocated to treatment group according to a stratified block randomisation scheme. Two strata were considered: centre (six centres) and location of the cyst (parenchymal vs extraparenchymal). Permuted blocks of size 4 and 6 were used to balance the treatment allocation within each stratum. The randomisation lists were kept in electronic form on a computer accessible only to the statistician. All other research staff were blinded to the treatment arm.

Statistical methods

All analyses were performed according to an intent to treat principle. Thus all patients randomised were included in the group to which they were initially assigned, regardless of adherence. All tests were conducted at the 0.05 two tailed significance level.

The primary outcome measure was disappearance of active cysts by 12 months of follow-up, evaluated through serial imaging studies. The χ^2 test was used to compare the proportion of patients free of active cysts at 12 months. We also explored active cyst disappearance before 12 months and the possible interaction of drug treatment with the patient's weight (as a continuous variable and as a categorical variable defined as

≤ 60 kg) in predicting active cyst disappearance using both stratified analysis and logistic regression.

Secondary outcomes included disappearance of transitional or calcified cysts at 1, 6 and 12 months, change in number of cysts in a specific phase, time to seizure recurrence and adverse events. For examining secondary outcomes, we used the Wilcoxon rank sum test to look at the change in the number of cysts between follow-up images. Kaplan–Meier curves and the log rank test were used to estimate time to seizure recurrence in the two treatment groups¹⁷; the χ^2 or Fisher's exact test was used to evaluate differences in potential adverse events during treatment and for the first month following treatment.

Follow-up

After treatment completion, patients were seen at 2 weeks, 1 month and every 3 months thereafter. Repeat scans were performed at 1 month, 6 months and 1 year after study entry.

RESULTS

Participants

Between February 2001 and February 2003, 178 patients with NC agreed to participate in the study; 88 patients were randomised to the ALB group and 90 to the placebo group (fig 1). Follow-up continued until February 2005.

Baseline data for all randomised patients is provided in table 1 by treatment group. Age range was 3–82 years (mean 39.4 years). Only 15 (9%) of the patients were less than 18 years old. Fifty-six per cent of the patients were men. After taking into account early withdrawals (eight patients withdrew after randomisation but before taking study medication), there were 84 cases in the active treatment arm and 86 cases in the placebo treatment arm (fig 1). Of the 107 patients with new onset seizure as a symptom at baseline, 51 (48%) were randomised to active treatment and 56 (52%) were randomised to receive placebo. Patients randomised to ALB had a greater number of calcifications at baseline ($p=0.018$), but the frequency of lesions (active and transitional) and their location (parenchymal and extraparenchymal) were similar in the two treatment groups. Seventy-seven patients in each arm completed the entire 2 year follow-up period (fig 1).

Outcomes

Freedom from cysts

Active cysts were identified in 59 (69%) of the 86 people randomised to ALB and 57 (66%) of the 86 people in the placebo arm (table 2). By 12 months following treatment, 38% (20/53) of those with 12 month scans were free of active cysts in the treatment group compared with 20% (10/50) in the placebo group ($p=0.048$). This difference in cyst disappearance by treatment was greatest at 1 month of follow-up, with 31% (18/58) of those in the ALB group being free of active cysts at month 1 of follow-up compared with 7% (4/55) of those in the placebo group ($p=0.001$). Of those patients followed and scanned at 6 months, 35% (18/51) were free of active cysts in the treatment arm compared with 12% (6/50) in the placebo group ($p=0.006$). A similar trend was seen when looking at active parenchymal and extraparenchymal cysts separately, but the association was not statistically significant for extraparenchymal cysts (table 2). There was no significant interaction between the drug and the participant's weight in predicting the disappearance of active cysts.

Table 2 Number (valid %) of patients in whom cysts disappeared out of the total who had cysts of that type at baseline (%)

	Active cysts			Transitional cysts			Calcifications		
	Albendazole	Placebo	p Value for χ^2 test	Albendazole	Placebo	p Value for χ^2 test	Albendazole	Placebo	p Value for χ^2 test
All locations									
Baseline	0/59 (0)	0/57 (0)	Referent	0/49 (0)	0/54 (0)	Referent	0/38 (0)	0/32 (0)	Referent
1 month	18/58 (31.0)	4/55 (7.3)	0.001	13/47 (27.0)	12/52 (23.1)	0.600	30/37 (81.1)	20/30 (66.7)	0.178
6 month	18/51 (35.3)	6/50 (12.0)	0.006	22/42 (52.4)	19/49 (38.8)	0.194	28/34 (82.4)	18/28 (64.3)	0.106
12 month	20/53 (37.7)	10/50 (20.0)	0.048	23/42 (54.8)	27/51 (52.9)	0.861	27/33 (81.8)	23/30 (76.7)	0.614
Parenchymal									
Baseline	45/45 (0)	39/39 (0)	Referent	40/40 (0)	52/52 (0)	Referent			
1 month	18/44 (40.9)	4/37 (10.8)	0.002	11/38 (29.0)	14/50 (28.0)	0.922			
6 month	19/39 (48.7)	8/27 (22.9)	0.021	19/34 (55.9)	21/47 (44.7)	0.320			
12 month	20/41 (48.8)	7/36 (19.4)	0.007	20/34 (58.8)	29/49 (59.2)	0.974			
Extraparenchymal									
Baseline	28/28 (0)	30/30 (0)	Referent	11/11 (0)	13/13 (0)	Referent			
1 month	10/28 (35.7)	7/30 (23.3)	0.301	5/11 (45.5)	5/13 (38.5)	1.000*			
6 month	11/24 (45.8)	7/26 (26.9)	0.164	8/10 (80.0)	4/11 (36.4)	0.081*			
12 month	15/26 (57.7)	13/26 (50.0)	0.578	6/10 (60.0)	7/13 (53.9)	1.000*			

*Fisher's exact test.

Transitional cysts were identified in 49 (57%) of the 86 people randomised to ALB and in 54 (63%) of the 86 people in the placebo arm (table 2). By 1 month following treatment, 27% (13/47) of those with 1 month scans were free of transitional cysts in the treatment group compared with 23% (12/52) in the placebo group ($p=0.600$). Of those patients followed and scanned at 6 months, 52% (22/42) were free of transitional cysts in the treatment arm compared with 39% (19/49) in the placebo group ($p=0.194$). After 1 year of follow-up, 55% (23/42) of those in the treatment arm were free of transitional cysts compared with 53% (27/51) in the placebo group ($p=0.861$). There was also no significant difference in the disappearance of transitional cysts by drug treatment in the subanalyses by brain location (parenchymal or extraparenchymal) (table 2).

Reduction in the number of cysts

The number of active cysts apparent on a patient's CT or MRI during the study ranged from 0 to 36, excluding patients with too many active cysts to count (eight excluded at baseline, seven at months 1 and 6, and six excluded at month 12). The mean number of active cysts decreased between baseline and month 1 for the ALB (mean number at baseline 3.88 and at 1 month 1.86) group but not for the placebo group (mean at baseline 2.67 and at 1 month 2.69). We looked at the change in the number of cysts of each phase overall and by location in the brain (parenchymal or extraparenchymal) using the Wilcoxon

rank sum test. Those taking ALB had a significant decrease in the number of active cysts between baseline and month 1 compared with those in the placebo group ($p=0.001$). This trend is consistent when looking at all active cysts and only active parenchymal cysts ($p=0.002$) or active extraparenchymal cysts ($p=0.021$). There was no difference by treatment group in the change in the number of active cysts between month 1 and month 6 ($p=0.797$) or month 6 and month 12 of follow-up ($p=0.938$).

The number of transitional cysts apparent on a patient's CT or MRI during the study ranged from 0 to 38, after excluding those with too many transitional cysts to count (four excluded at baseline, five at month 1 and four at months 6 and 12). The total number of calcifications apparent on a patient's CT or MRI ranged from 0 to 45, excluding those with too many calcified cysts to count (six excluded at baseline, two at month 1, three at month 6 and four at month 12). The change in the number of transitional cysts and inactive calcifications between baseline and month 1 of follow-up did not differ by treatment group (p value for transitional cysts 0.234, p value for calcifications 0.456).

Seizure freedom

At baseline, 107 patients reported new onset of seizure. Of these, 51 (48%) were randomised to the ALB group and 56 (52%) to the placebo group. Using Kaplan–Meier survival analysis, the proportion of patients with seizure at baseline who were seizure free at 12 months of follow-up was 0.62 in the ALB group and 0.52 in the placebo group (fig 2). The mean time seizure free was 8.86 months in the ALB group versus 7.67 months in the placebo group; this difference was not statistically significant ($p=0.274$). Findings were similar to those with only parenchymal cysts ($p=0.318$) and those with any extraparenchymal cysts (with or without parenchymal cysts) ($p=0.998$). It was not possible to evaluate seizure outcome for those with only extraparenchymal cysts because the number with seizures at baseline was small (four patients).

Possible adverse events

The three most common symptoms reported during treatment and the first month following treatment were headache,

Figure 2 Per cent of patients with seizure at baseline who survived seizure free after treatment with albendazole or placebo over time

Table 3 Number of patients with possible adverse events by treatment (% of valid responses to question)

Symptom	No (valid %) with symptom in albendazole group	No (valid %) with symptom in placebo group	p Value for χ^2 test
During 8 days of treatment			
Seizures	2 (2.4)	3 (3.5)	1.00*
Headache	59 (70.2)	53 (61.6)	0.236
Stomach problems (nausea, pain or vomiting)	38 (45.2)	40 (46.5)	0.868
Intracranial hypertension	0 (0)	3 (0.5)	0.246*
During first month following treatment			
Seizures	8 (9.8)	10 (12.0)	0.637
Headache	50 (61.0)	51 (61.4)	0.951
Stomach problems (nausea, pain or vomiting)	9 (11.0)	13 (15.7)	0.376
Intracranial hypertension	0 (0)	0 (0)	NA

*Fisher's exact test.

seizures and stomach problems (table 3). During the 8 days of treatment, three patients developed intracranial hypertension, all in the placebo group (table 3).

During the 2 year study period, seven people died, all but one due to cysticercosis. Two of the deaths occurred in the treatment group and five in the placebo group (fig 1). This difference was not statistically significant (Fisher's exact test $p = 0.213$). All but one of the deceased patients presented with the extraparenchymal form of NC, and four of the six had been shunted more than 1 year prior to study enrolment. Repeat shunting was performed in four patients with generally poor outcome. Shunting of NC patients is generally associated with a high shunt failure rate¹⁸ and high mortality.^{19 20}

DISCUSSION

Our primary analysis of active cyst disappearance by 12 months revealed a clear advantage for the ALB group compared with placebo, and the effect occurred within the first 30 days following initiation of treatment. There seems to be no additional advantage in the treatment group compared with placebo after this time. The reduction in the number of active cysts was also most pronounced at 1 month. Nonetheless, about 70% of people are not rendered free of active cysts with this first course of therapy. These results are similar to those reported by Garcia and colleagues.⁵ At 6 months after treatment, active cysts disappeared in 38% of patients receiving ALB plus steroids compared with 15% of patients receiving placebo alone. We also confirm previous reports regarding the lack of effectiveness of ALB treatment on transitional or degenerative cysts.^{21–25}

About half of the people with seizures at baseline remained seizure free at 1 year following initiation of treatment, and there was no significant effect of treatment with ALB on this outcome. This finding is similar to that obtained in our previous trial,²⁶ two observational studies^{2 27} and two trials involving paediatric patients.^{28 29} However, several studies have found a significant reduction in seizures in patients treated with ALB, including two clinical trials with children,^{21 30} and a meta analysis.¹¹ A recent trial in adult patients did not find a reduction in the number of seizures overall, but did report a significant reduction in the number of generalised seizures in patients treated with ALB and steroids compared with those treated with only placebo.⁵ Thus the findings regarding the influence of ALB on seizure recurrence are inconsistent.

However, there is no indication that ALB treatment increases the risk of seizures or any other adverse event. Symptoms during treatment and for the first month following treatment were similar in the ALB and placebo groups.

An important question that remains is the effect of ALB on extraparenchymal cysts. The association of treatment with the disappearance of active extraparenchymal cysts was not significant, although there was the suggestion of a trend. We did find a significant reduction in the number of active extraparenchymal cysts in the ALB group compared with the placebo group between baseline and month 1. This difference in the results by outcome (disappearance versus number of active cysts) may be due to a lack of statistical power to address cyst disappearance.

If the objective of treatment is to eradicate active cysts, it would appear that a single course of therapy with ALB (the usual practice) provides benefit over placebo in only 24% of patients. Since 69% of patients receiving ALB continue to demonstrate active cysts, new drugs or different treatment regimens need to be developed for this majority of patients with NC. Our finding that not all encysted parasites die after a single course of antiparasitic treatment was also described in a recent literature review.³¹ Treatment options to be explored may include a higher initial dose of drug, concomitant or subsequent treatment with an AHD that has a different mode of action, such as praziquantel, or a repeat course of ALB or of another AHD in those with persistent active cysts at 1 month. We also need studies to explore reasons for the heterogeneous effect of ALB to guide the development of treatment strategies for the large proportion of patients who do not seem to benefit from ALB.

Acknowledgements: We are indebted to Drs Eduardo Castro, Gastón Rodríguez, Iván Reinoso, Víctor Paredes and Carlos Barriónuevo of the "Carlos Andrade Marín" Hospital of Quito, Ecuador, for support in patient care, and to Dr Franklin Santillán of the Social Security Hospital of Cuenca, Ecuador, for patient referrals. Other members of the Neurocysticercosis Clinical Trial Group who collaborated in this study include: Karina Quinde, Research Assistant; Ana Montenegro, Research Social Worker; Alicia Vasco, Research Nurse; Mery Obregon, Research Nurse; Luis Villalta, Accountant; Nora Hernandez, MD, Project Coordinator; Mary Angie Garcia, Research Assistant. The authors of this manuscript participated in the study design and implementation, as well as in the data analysis and/or manuscript preparation.

Funding: This study was supported by NINDS grant #R01-NS39403; Glaxo/SKB and Acromax Co supplied active drug and placebo.

Competing interests: None.

Ethics approval: Approval for the study was granted by the Institutional Review Board of Columbia University, the Office for Human Research Protection (OHRP) of the National Institutes of Health in the USA, as well as the ethics committees at each of the participating hospitals.

The Ecuadorian Neurocysticercosis Group: Noemi Lisanti, ("Comprehensive Epilepsy Center", Cuenca), Rafael Aguirre, ("Teodoro Maldonado" Hospital, Guayaquil), Marcos Serrano, ("Carlos Andrade Marín" Hospital, Quito), Jorge Pesantes, Jorge Moncayo, ("Eugenio Espejo" Hospital, Quito) and Marcelo Roman, ("Baca Ortiz" Hospital, Quito).

REFERENCES

1. White A. Neurocysticercosis. *Curr Treat Options Infect Dis* 2000;**2**:78–87.
2. Carpio A, Hauser W. Prognosis for seizure recurrence in patients with newly diagnosed neurocysticercosis. *Neurology* 2002;**59**:1730–4.
3. Hawk M, Shalhale K, Kim K, et al. Neurocysticercosis in the United States: review of an important emerging infection. *Neurology* 2004;**63**:1559–64.
4. Schantz P. *Taenia solium cysticercosis: an overview of global distribution and transmission*. Oxon, UK: CAB International, 2002:63–74.
5. Garcia H, Pretell E, Gilman R, et al. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. *N Engl J Med* 2004;**350**:249–58.
6. Singh G, Sander J. Anticysticercal treatment and seizures in neurocysticercosis. *Lancet Neurol* 2004;**3**:207–8.
7. Takayanagui O. Therapy for neurocysticercosis. *Expert Rev Neurother* 2004;**4**:129–39.
8. Caplan L, Estanol B, Mitchel W, et al. How to manage patients with neurocysticercosis. *Eur Neurol* 1997;**37**:124–31.
9. Salinas R, Prasad K. *Drugs for treating neurocysticercosis (tapeworm infection of the brain)*. Oxford: Update Software, 2005.
10. Carpio A, Escobar A, Hauser W. Cysticercosis and epilepsy: a critical review. *Epilepsia* 1998;**39**:1025–40.
11. Del Brutto O, Roos K, Coffey C, et al. Meta-analysis: Cysticidal drugs for neurocysticercosis: albendazole and praziquantel. *Ann Intern Med* 2006;**145**:43–51.
12. Evans C, Garcia H, Gilman R, et al. Controversies in the management of cysticercosis. *Emerg Infect Dis* 1997;**3**:403–5.
13. Carpio A, Placencia M, Santillán F, et al. A proposal for a classification of neurocysticercosis. *Can J Neuro Sci* 1994;**21**:43–7.
14. Garcia HH, Gilman RH, Horton J, et al. Albendazole therapy for neurocysticercosis: a prospective double-blind trial comparing 7 versus 14 days of treatment. Cysticercosis Working Group in Peru. *Neurology* 1997;**48**:1421–7.
15. GlaxoSmithKline. ALBENZA. Available at: http://us.gsk.com/products/assets/us_albenza.pdf (accessed 24 June 2008).
16. Fleiss J. *Statistical methods for rates and proportions*. New York: John Wiley & Sons, 1981:218.
17. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. *JASA* 1958;**53**:457–81.
18. Kelley R, Duong D, Locke G. Characteristics of ventricular shunt malfunctions among patients with neurocysticercosis. *Neurosurgery* 2002;**50**:757–62.
19. Colli B, Pereira C, Assirati JJ, et al. Isolated fourth ventricle in neurocysticercosis: pathophysiology, diagnosis, and treatment. *Surg Neurol* 1993;**39**:305–10.
20. McCormick G. Cysticercosis—review of 230 patients. *Bull Clin Neurosci* 1985;**50**:76–101.
21. Singhi P, Jain V, Khandelwal N. Corticosteroids versus albendazole for treatment of single small enhancing computed tomographic lesions in children with neurocysticercosis. *J Child Neurol* 2004;**19**:323–7.
22. Padma M, Behari M, Misra N, et al. Albendazole in single CT ring lesions in epilepsy. *Neurology* 1994;**44**:1344–6.
23. Rajshekhar V. Rate of spontaneous resolution of a solitary cysticercus granuloma in patients with seizures. *Neurology* 2001;**57**:2315–17.
24. Gogia S, Talukdar B, Choudhury V, et al. Neurocysticercosis in children: clinical findings and response to albendazole therapy in a randomized, double-blind, placebo-controlled trial in newly diagnosed cases. *Trans R Soc Trop Med Hyg* 2003;**97**:416–21.
25. Garcia H, Evans C, Nash T, et al. Current consensus guidelines for treatment of neurocysticercosis. *Clin Microbiol Rev* 2002;**15**:747–56.
26. Carpio A, Santillán F, León P, et al. Is the course of neurocysticercosis modified by treatment with antihelminthic agents? *Arch Int Med* 1995;**155**:1982–8.
27. Rajshekhar V, Lakshmanan J. Seizure outcome in patients with a solitary cerebral cysticercus granulomas. *Neurology* 2004;**62**:2236–40.
28. Baranwal AK, Singhi PD, Khandelwal N, et al. Albendazole therapy in children with focal seizures and single small enhancing computerized tomographic lesions: a randomized, placebo-controlled, double blind trial. *Pediatr Infect Dis J* 1998;**17**:696–700.
29. Gogia S, Talukdar B, Choudhury V, et al. Neurocysticercosis in children: clinical findings and response to albendazole therapy in a randomized, double-blind, placebo-controlled trial in newly diagnosed cases. *Trans R Soc Trop Med Hyg* 2003;**97**:416–21.
30. Kalra V, Dua T, Kumar V. Efficacy of albendazole and short-course dexamethasone treatment in children with 1 or 2 ring-enhancing lesions of neurocysticercosis: a randomized controlled trial. *J Pediatr* 2003;**143**:111–14.
31. Nash T, Singh G, White A, et al. Treatment of neurocysticercosis: current status and future research needs. *Neurology* 2006;**67**:1120–7.